PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.
Phase 2
Completed
- Conditions
- Covid19 Vaccine
- Interventions
- Biological: Pfizer-BioNTech COVID-19 vaccineBiological: PTX-COVID19-BBiological: Placebo
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Providence Therapeutics Holdings Inc.
- Target Recruit Count
- 565
- Registration Number
- NCT05175742
- Locations
- 🇨🇦
Malton Medical, Mississauga, Ontario, Canada
🇨🇦Red Maple, Ottawa, Ontario, Canada
🇨🇦Pharma Medica Research Inc., Toronto, Ontario, Canada
PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64
Phase 1
Completed
- Conditions
- Covid19 Vaccine
- Interventions
- Biological: PlaceboBiological: PTX-COVID19-B
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Providence Therapeutics Holdings Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04765436
- Locations
- 🇨🇦
Manna Research, Toronto, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath